Home › Funds › Fairmount Funds Management LLC › JBIO

Fairmount Funds Management LLC position in JBIO

JADE BIOSCIENCES INC · Health Care

Fairmount Funds Management LLC reported holding 4,553,494 shares of JBIO (JADE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$101.2M, representing 6.69% of its reported portfolio and ranking #5 among its reported holdings. Fairmount Funds Management LLC has disclosed JBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)4.55M sh
Reported value held$101.18M
Portfolio Weight6.69%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Fairmount Funds Management LLC's JBIO position evolved

Fairmount Funds Management LLC first disclosed a stake in JBIO in Q2 2025 at 3,220,368 shares (US$32.2M). The position peaked in Q2 2026 at 4,553,494 shares, worth US$101.2M. Across 5 filings, Fairmount Funds Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 4,553,494 shares valued at US$101.2M. Notable position changes include a 41% increase in Q4 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 3.22M $32.17M New
Q3 2025 3.22M $27.79M Hold
Q4 2025 4.55M $70.26M Add
Q1 2026 4.55M $63.98M Hold
Q2 2026 4.55M $101.18M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JBIO and 13F data

JBIO (JADE BIOSCIENCES INC) is a Health Care company. 106 other funds we track also report a position in JBIO — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M), Bellevue Group AG (US$67.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JBIO

All JBIO fund holders →

FAQ

How long has Fairmount Funds Management LLC held JBIO?

Fairmount Funds Management LLC has disclosed JBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Fairmount Funds Management LLC's current position in JBIO?

As of Q2 2026, Fairmount Funds Management LLC holds 4.55M shares of JBIO (JADE BIOSCIENCES INC), valued at $101.18M, representing 6.69% of its reported portfolio and ranking #5.

Has Fairmount Funds Management LLC been buying or selling JBIO?

In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in JBIO. The position peaked in Q2 2026 at 4.55M shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, Bellevue Group AG, among 106 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.